Models of cancer

Models of cancer come in a variety of forms, from cancer cell lines in culture to genetically modified mice. In between are a host of organisms that also contribute to our understanding of this disease. Yeast, for example, have added much to our knowledge of the cell cycle and the maintenance of cell polarity, whereas egg extracts from Xenopus laevis have helped our comprehension of biochemical pathways and protein modifications essential for normal cellular function. Work on Caenorhabditis elegans was crucial for our grasp of the genetic pathway that regulates programmed cell death, and research in Drosophila melanogaster has identified several pathways that are deregulated during cancer formation, including the Hippo tumour suppressor pathway. Whether results are generated by cell lines, yeast, mouse orthotopic tumour models or zebrafish the cumulative information from these models should help us to understand in greater detail the subtleties of cancer formation.


2013

September 2013 Vol 13 No 9

Zebrafish cancer: the state of the art and the path forward

Richard White, Kristin Rose & Leonard Zon

doi:10.1038/nrc3589

March 2013 Vol 13 No 3

Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics

Cayetano Gonzalez

doi:10.1038/nrc3461

2011

January 2011 Vol 11 No 1

Cell lineage and cell death: Caenorhabditis elegans and cancer research

Malia B. Potts & Scott Cameron

doi:10.1038/nrc2984

2010

October 2010 Vol 10 No 10

Harnessing transposons for cancer gene discovery

Neal G. Copeland & Nancy A. Jenkins

doi:10.1038/nrc2916

July 2010 Vol 10 No 7

Non-germline genetically engineered mouse models for translational cancer research

Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe & Lynda Chin

doi:10.1038/nrc2877

June 2010 Vol 10 No 6

Cell line misidentification: the beginning of the end

American Type Culture Collection Standards Development Organization Workgroup ASN-0002

doi:10.1038/nrc2852

April 2010 Vol 10 No 4

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Sreenath V. Sharma, Daniel A. Haber & Jeff Settleman

doi:10.1038/nrc2820


Top

Extra navigation

natureevents

Advertisement